The pact links two big players in the vaccine world that both missed out on the rush to develop and commercialize Covid shots ...
The cash infusion is likely to strengthen the balance sheet of the vaccine maker, whose shares lost more than 98% of their ...
Novavax said it would co-commercialize its Covid-19 vaccine with French drugmaker Sanofi and develop new Covid-19-influenza ...
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Shares in Novavax almost doubled ...
Sanofi on Friday said it had reached a deal worth up to $1.2 billion to sell Novavax’s Covid shot as well as to try to ...
Sanofi and Novavax partnered for a COVID-19 vaccine deal. Novavax will receive $1.2 billion in milestones. Sanofi will take ...
"We're excited by the prospect of combining Novavax's adjuvanted COVID-19 vaccine that has shown high efficacy and favorable ...
The recent run of good fortune for vaccine maker Novavax (NASDAQ:NVAX continues. Following the major licensing deal with ...
Novavax shares (NVAX) surged after the vaccine maker said it had struck a licensing deal worth up to $1.4 billion with Sanofi ...
Hedge fund Shah Capital said on Monday it would withdraw its campaign against the re-election of three directors on Novavax's ...
Novavax shares jumped 50% on Monday following its recent licensing deal with Sanofi, as meme stocks are making a 2021-style ...
Novavax (NVAX) shares are skyrocketing after the company announced a $1.2 billion deal with French drugmaker Sanofi (SNY). B.